There are 383 resources available
163P - Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial
Presenter: Carminia Maria Della Corte
Session: Poster Display session
164P - Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients
Presenter: Luca Cantini
Session: Poster Display session
165P - Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first line immunotherapy-based regimens
Presenter: Giulia Mazzaschi
Session: Poster Display session
166P - Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients
Presenter: Shouzheng Wang
Session: Poster Display session
167P - KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
Presenter: Laura Pinto
Session: Poster Display session
168P - Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α
Presenter: Kirsten De Ridder
Session: Poster Display session
169P - Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling
Presenter: Marco Tagliamento
Session: Poster Display session
170P - Clonal hematopoiesis in asymptomatic individuals enrolled in a lung cancer screening program
Presenter: Luis Montuenga
Session: Poster Display session
171P - Detection of NTRK1/2/3 rearrangements by PCR test for 5’/3’-end unbalanced expression
Presenter: Evgeny Imyanitov
Session: Poster Display session
173P - Genomic characteristics and its correlations with tumor mutational burden and PD-L1 expression in Chinese lung squamous cell carcinoma
Presenter: Yangtian Chen
Session: Poster Display session